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Background: Establishing a confident clinical diagnosis before an advanced stage of illness can be difficult in
Creutzfeldt-Jakob disease (CJD) but unlike common causes of dementia, prion diseases can often be diagnosed by
identifying characteristic MRI signal changes. However, it is not known how often CJD-associated MRI changes are
identified at the initial imaging report, whether the most sensitive sequences are used, and what impact
MRI-diagnosis has on prompt referral to clinical trial-like studies.
Methods: We reviewed the MRI scans of 103 patients with CJD referred to the National Prion Clinic since 2007 and
reviewed the presence of CJD-associated changes, compared these findings with the formal report from the
referring centre and reviewed the types of sequence performed.
Results: In sCJD we found CJD-associated MRI changes in 83 of 91 cases (91% sensitivity). However, the referring
centres documented CJD-associated MRI changes in 43 of the sCJD cases (47% sensitivity). The most common
region not documented by referring centres was the cortex (23 of 68 sCJD cases), but there was a statistically
significant discrepancy in all regions (p<0.0001). Patients in whom MRI abnormalities were missed by the referring
hospital were more advanced at the time of recruitment to a clinical trial-like study (p=0.03).
Conclusions: CJD-associated MRI changes are often not documented on the formal investigation report at the
referring centre. This is important as delay makes enrolment to clinical trials futile because of highly advanced
disease. If a diagnosis of CJD is suspected, even if the initial imaging is reported as normal, a specialist MRI review
either by an experienced neuroradiologist or by a prion disease specialist unit could facilitate earlier diagnosis.
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Creutzfeldt-Jakob disease occurs as a sporadic, iatro-
genic and genetic fatal neurodegenerative disorder [1].
With the exception of genetic types, CJD can only be de-
finitively diagnosed by tissue examination, usually brain
biopsy or at autopsy. However, using clinical and investi-
gative criteria, WHO sought to define the likelihood that
a patient has CJD. The original criteria include dementia
with variety of neurological signs, the presence of 14.3.3
proteins in the CSF and characteristic EEG with pseudo-
periodic complexes. More recently MRI criteria have
been added giving a sensitivity and specificity >90% for* Correspondence: h.hyare@prions.ucl.ac.uk
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reproduction in any medium, provided the orprobable CJD [2,3]. These changes comprise alterations
on diffusion weighted (DWI) and FLAIR images in the
basal ganglia, thalamus and cortex [4,5]. However these
changes can be subtle and easily missed by a clinician
unfamiliar with such a rare disorder. With the develop-
ment of potential therapies to alter the natural history of
the disease early diagnosis is essential to give the max-
imum chance of salvaging functional brain tissue [6]. As
MRI is the most widely available non-invasive test assist-
ing diagnosis, it is important that clinicians are aware of
the imaging features. At present it is not known how
often the MRI abnormalities are reported by radiologists
in cases of definite CJD. We therefore reviewed images
from 133 consecutive patients referred to the National
Prion Clinic and compared the report from the referring
clinician and our own specialist radiologists; 103 werel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In 2004 the Chief Medical Officer wrote to UK neurolo-
gists requesting that all patients with suspected CJD are
referred to both the National CJD Surveillance Unit in
Edinburgh and the National Prion Clinic (NPC) based at
the National Hospital for Neurology and Neurosurgery
(NHNN), London. All patients underwent PRNP analysis
for genetic mutations. MRI scans from all visited patients
are requested by the NPC. The scans studied in this work
were from patients who were referred to the NPC by
their local physician with full consent and the patients
were enrolled into either the clinical trial PRION-1 or
the on-going National Prion Monitoring Cohort study.
Both studies were approved by the Eastern Medical
Research Ethics Committee and are compliant with
the Helsinki Declaration.
MRI evaluation and reporting
NPC MRI review The first MRI scan were reviewed by
one of two senior neuroradiologists (H.H. and J.S.) at
The National Hospital for Neurology and Neurosurgery
(NHNN and the NPC). The radiologists were aware of
the suspicion of CJD at the time of reporting but were
not aware of the results of any biopsy or post mortem
results at the time of reporting. The available MRI se-
quences were reviewed together as the sensitivity of indi-
vidual sequences was not being compared. Three types of
high signal intensity lesions were accepted as CJD-
associated MRI changes on DWI and/or Fluid Atte-
nuated Inversion Recovery (FLAIR) and/or T2-weighted
sequences:
1. Lesions in the striatum (caudate or putamen or both)
2. Lesions in the thalamus including the pulvinar
3. Lesions along the cortical ribbon (cerebral or
cerebellar)
External MRI formal report review All external reports
were reviewed for whether:
1. The MRI was normal
2. The MRI differential diagnosis included CJD
3. CJD-associated abnormalities were specifically
documented in the caudate, putamen, thalamus or
cortex
Exclusion criteria and classification
All patients in whom a clinical diagnosis other than CJD
was suspected, or those who did not fulfil the criteria forCJD were excluded, as were all scans before 2007 when
specific scan review was not routine. Patients who were
referred to the NPC with a suspected diagnosis of inhe-
rited prion disease (IPD) were also excluded, as prion
gene sequencing resulted in a definite diagnosis and
MRI rarely shows any signal change with the majority of
mutations. Two cases with the E200K mutation and one
case with the P102L mutation detected at a later stage
were included as the clinical picture at the time was in-
distinguishable from sCJD.
The remaining patients were categorised by CJD type
with all available investigations; those with sporadic CJD
were further sub-categorised at the time of initial referral
as: possible, probable or definite using the WHO criteria.
We then re-classified the sCJD patients using the modi-
fied criteria suggested by Zerr et al. [3] for both the re-
ferred MRI report and then our own MRI impression to
see whether our MRI interpretation altered the classifi-
cation of these patients. Where available, the scales data
was documented, based on a composite functional scale
derived from the Barthel ADL index and Clinical De-
mentia Rating Scale Sum of Boxes.
Statistical analysis
The patient population characteristics and the compari-
son of the presence of CJD-associated MRI images be-
tween NPC and referring centre were assessed using the
Chi2 test (GraphPad Prism).
Results
We obtained 133 MRI scans from 113 patients referred
to the NPC between 01.03.2007 and 24.05.2010 with a
suspected diagnosis of CJD. 30 scans were excluded: 21
cases did not fulfil the WHO diagnostic criteria for CJD
or were thought clinically to be due to a different cause;
the referring report could not be obtained in 9 cases.
A total of 103 reported scans were available for review
of which 56% were from males. The eventual diagnosis
was sCJD in 91 cases with a median age of onset of
65 years (3 possible, 35 probable and 53 definite). Two
cases of iatrogenic CJD (iCJD) from cadaver sourced
growth hormone were identified (both 41 years old when
symptomatic), 3 patients with inherited prion disease
and 7 patients had vCJD with a median age of onset of
22 (2 probable and 5 definite) (Table 1).
In sCJD, we found characteristic increases in MRI sig-
nal intensity in 83 of the 91 cases at NPC review, a sen-
sitivity of 91% for MRI in the diagnosis of CJD in this
series (Table 1). CJD-associated changes were not de-
tected in 8 a total of cases, 2 of whom did not have a
DWI (2 definite sCJD). The remaining 6 cases had a
DWI sequence performed (two definite, three probable
and one possible sCJD) (Table 1). The referring centres,
however, described CJD-associated MRI changes in 43 of























sCJD 3 35 53 91 65 (38–85) 75 (82) 83 (91) 43** (47) 55 (60) 19 (43%)
vCJD 2 5 7 22 (20–53) 6 (86) 7* (100) 7 (100) 5 (71) 0
iCJD 2 2 41 (0) 1 2 0 2 (100) 2 (100)
IPD 3 3 1 - -
E200K 2 67 (63–70) - 2 0 0 -
P102L 1 61 (0) - 1 1 0 -
The scans and corresponding reports of 103 CJD patients were reviewed. The population comprised 91 sCJD, 7 vCJD, 2 iCJD and 3 IPD patients. The number of
scans with DWI is shown as is the incidence of CJD-associated changes as noted by NPC and referring centre.
*= 2 of the 7 patients had MRI changes normally associated with sCJD.
**= p<0.0001 compared with NPC opinion of CJD-associated changes using Chi2 with 1df and Yates’ correction.
Figure 1 The MRI scans of 91 patients with sCJD were reviewed
and compared with the corresponding report from the
referring centre. The overall sensitivity of MRI scans found by the
NPC was 91% compared with 47% from the referring centre
(p<0.0001). The NPC found that 74% of cases had cortical high
signal, 73% of cases had changes in the caudate, 59% of cases had
changes in the putamen and 37% in the thalamus. The region that
there was the most discrepancy between the two impressions was
the cortex but there was a significant difference in all regions
evaluated (p<0.0001).
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CJD-associated MRI changes in 40 of the 83 sCJD cases
found to have MRI changes at NPC review (p<0. 0001
compared with our identification of similar changes
using Chi2 with Yates’ correction and 1 degree of free-
dom). In cases with unreported CJD-associated MRI
changes, there was no significant difference between
cases referred from a neurological centre or general hos-
pital (Table 1). Occasionally CJD-associated MRI changes
were commented upon but thought to be calcification of
the basal ganglia, but more commonly there was no
mention of critical thalamic/cortical signal changes.
To further investigate whether referring centres identi-
fied CJD-associated MRI changes we reviewed specific
locations of increased MRI signal in sCJD cases (Figure 1).
We found that the most common sites for CJD-associated
MRI changes were cortex (74%) (Additional file 1: Figure
S1B and S1C) and caudate (73%) with thalamus being the
least affected (37%) (Figure 1). The most common region
not documented by referring centres was the cortex (23 of
68 sCJD cases), but there was a statistically significant dis-
crepancy in all regions (p<0.0001 Figure 1).
All reports of vCJD were concordant with our own.
Interestingly, two definite cases did not have a pulvinar
signal increase greater than that of the basal ganglia and
were initially classified as sCJD. In contrast, both iCJD
cases were initially reported to have had normal scans
(Table 1, Additional file 1: Figure S1A). When the diag-
nosis was categorised according to the modified criteria
suggested by Zerr et al. [3] at the time the patient pre-
sented to the NPC, using the MRI report and our own
MRI impression, we found that the diagnosis changed
from possible to probable sCJD in only two cases as all
other patients with negatively reported scans had either
characteristic EEG changes or positive CSF 14-3-3 pro-
tein (data not shown).
DWI sequences were performed in 83 of the 103 MRI
studies (79%) (Table 1). In the 20 patients for whomDWI was not performed, CJD-associated MRI changes
were detected in 16 MRI studies. In all the MRI studies,
FLAIR and T2-weighted sequences were present.
A subset of the cohort which included 62 patients
were rapidly reviewed by the National Prion Clinic team
and scales data obtained based on a composite func-
tional scale derived from the Barthel ADL index and
Clinical Dementia Rating Scale Sum of Boxes. Where
the MRI abnormalities were detected by the referring
hospital (n=40), patients had a significantly higher (less
advanced disease) (p=0.03) median functional score of
5/35 (range 0–31) compared to median MRC score of
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missed by the referring hospital (n=22).
Discussion
We have shown that MRI signal changes are often not
identified on initial scan at referring hospitals in patients
with CJD. Signal abnormality characteristically occurs in
the basal ganglia and thalamus [7-9] but this was
reported in only about half the referred patients and cor-
tical abnormalities were reported in even fewer patients.
Missed diagnosis was associated with a more advanced
clinical state at enrolment in clinical-trial like studies.
There are a number of reasons why the MRI signal ab-
normalities were not reported by the referring clinicians.
Firstly, the rarity of CJD means radiologists, even in a
neurological centre, have not seen many cases and will
be unfamiliar with the characteristic MRI findings. Sec-
ondly, it is possible that CJD at the time of original scan-
ning was not suspected, or was not mentioned on the
original request for MRI scanning, which would make the
radiologist consider a much wider range of possibilities.
The heightened suspicion of CJD at referral to our centre
is highly likely to be a factor in the increased ascertain-
ment. It is possible that after joint multidisciplinary meet-
ings with added clinical information, new interpretations
of the scan were not updated on the actual MRI report.
Thirdly, abnormality can be difficult to detect when
the MRI is degraded by movement artefact, a common
phenomenon in confused patients with CJD. In these
situations, it is even more imperative to perform a DWI
sequence which is relatively short compared to other
MRI sequences and can provide good quality informa-
tion in an uncooperative patient. Despite the inclusion
of DWI sequences in many routine MRI protocols, we
found that DWI was only performed in 79% of MRI
studies. When a patient is uncooperative, performing the
DWI sequence earlier in an MRI protocol may be more
helpful than persisting in acquiring good quality images
in other sequences.
Finally, the MRI abnormalities may have been detected
but dismissed as artefact and not reported. Increased
signal abnormality in the neocortex was seen in 17% of
controls subjects in a study by Young et al. [4] which
could lead to caution in interpretation of DWI findings
by many radiologists. However, visualisation of the
DWI-trace image in conjunction with the Apparent Dif-
fusion Coefficient (ADC) map where corresponding de-
creased signal is seen (Additional file 1: Figure S1D), can
confirm initial suspicion of DWI abnormalities. Perform-
ing an additional DWI sequence at a high b-value such as
b=3000 s/mm2 can increase confidence when DWI signal
abnormality is suspected [10]. DWI using a standard b-
value of 1000 s/mm2 and a high b-value of 3000 s/mm2
are routinely performed as part of the MRI Protocol forthe diagnosis of prion diseases at our institution. Asym-
metrical cortical or deep grey nuclei involvement can
also increase confidence in abnormal signal interpret-
ation. Nevertheless cortical ribboning must be inter-
preted with caution; this particularly applies to use of
machines with field strength higher than 1.5 T used in
the present study.
We found evidence of a less advanced clinical state
once patients were referred to our centre in patients
where the MRI abnormalities were detected by the refer-
ring centre compared to those where the MRI abnormal-
ities were initially missed. At present a high proportion
of CJD patient present to specialist centres with very
advanced neurodisability (often within a few days of
death) when clinical trials are futile. MRI is usually one
of the initial investigations when a patient is admitted
which could allow a clinical diagnosis to be made at an
earlier stage, avoiding uncertainty amongst patient rela-
tives and the need for further unnecessary investigations.
We believe that in patients where the initial MRI find-
ings were missed by the referring centre, further investi-
gation delayed referral leading to a more advanced
clinical state at specialist referral.
Conclusion
MRI is a useful tool in the diagnosis of CJD but the
characteristic changes are often not identified at initial
scan in the early stages of disease. This does not imply
an adverse criticism of the radiologists who have prob-
ably never, or rarely seen, an MRI from a patient with
CJD and to whom the diagnosis has not been raised as a
possibility. However CJD MRI findings have been
reported in the literature for over a decade and it is im-
portant if experimental therapeutics are to be success-
fully tested in human trials. If a diagnosis of CJD is
suspected, even if the initial imaging is interpreted as
normal, specialist MRI review either by an experienced
neuroradiologist or by a prion disease specialist unit
could facilitate earlier diagnosis.Additional file
Additional file 1: Figure S1. Selection of 4 cases from the 40 cases
where CJD-associated MRI changes were missed at the referring centre.
(A) A probable iCJD (growth hormone treated) patient: axial T2W images
demonstrates hyperintensity within the basal ganglia and thalamus
bilaterally; (B) A “probable” sCJD patient: axial DWI images show cortical
hyperintensity in the frontal cortex bilaterally; (C) A “definite” sCJD
patient: axial DWI shows hyperintensity in the head of caudate nucleus
and occipital cortex bilaterally; (D) A “definite” sCJD patient: axial ADC
map demonstrates restricted diffusion in the head of caudate and
putamen bilaterally.
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